Patents Assigned to TetraLogic Pharmaceuticals
-
Publication number: 20120094917Abstract: The present invention describes compounds, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy.Type: ApplicationFiled: May 25, 2010Publication date: April 19, 2012Applicant: TETRALOGIC PHARMACEUTICALS CORPInventors: Stephen M. Condon, Yijun Deng, Matthew D. Alexander, Matthew G. Laporte
-
Patent number: 8143426Abstract: Smac mimetics that inhibit IAPs.Type: GrantFiled: July 24, 2007Date of Patent: March 27, 2012Assignee: TetraLogic Pharmaceuticals CorporationInventors: Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippin
-
Publication number: 20110305777Abstract: Smac mimetics that inhibit IAPs.Type: ApplicationFiled: June 9, 2011Publication date: December 15, 2011Applicant: Tetralogic Pharmaceuticals CorporationInventors: Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippin
-
Publication number: 20110294827Abstract: IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less that 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposes are also disclosed.Type: ApplicationFiled: June 3, 2011Publication date: December 1, 2011Applicant: TETRALOGIC PHARMACEUTICALS CORPORATIONInventors: Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippin
-
Publication number: 20110287001Abstract: The invention provides methods for inducing apoptosis, comprising treatment of a patient with a TNF? inhibitor as well as with an IAP inhibitor and a TRAIL receptor agonist. The methods ameliorate the risk of unwanted effects, thereby resulting in an improved therapeutic index for IAP inhibitors in combination with a TRAIL receptor agonist.Type: ApplicationFiled: August 5, 2009Publication date: November 24, 2011Applicants: TETRALOGIC PHARMACEUTICALS, AMGEN INC.Inventors: Pamela M. Holland, Julia C. Piasecki, Christopher A. Benetatos, Srinivas K. Chunduru, Mark A. McKinlay
-
Patent number: 8022230Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language.Type: GrantFiled: March 13, 2009Date of Patent: September 20, 2011Assignee: TetraLogic Pharmaceuticals CorporationInventors: Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippin
-
Patent number: 7985735Abstract: Smac mimetics that inhibit IAPs.Type: GrantFiled: July 24, 2007Date of Patent: July 26, 2011Assignee: Tetralogic Pharmaceuticals CorporationInventors: Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippin
-
Patent number: 7968590Abstract: IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less that 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposes are also disclosed.Type: GrantFiled: October 9, 2008Date of Patent: June 28, 2011Assignee: Tetralogic Pharmaceuticals CorporationInventors: Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippin
-
Publication number: 20110008802Abstract: TNF? gene expression can be used as a biomarker of a cell's sensitivity to antagonists of inhibitor of apoptosis proteins (IAPs). Methods of the invention are useful for screening patients to identify those who could benefit from administration of an IAP antagonist to treat various malignant or benign tumors, benign proliferative diseases, or autoimmune diseases.Type: ApplicationFiled: May 7, 2008Publication date: January 13, 2011Applicant: TETRALOGIC PHARMACEUTICALS CORP.Inventors: Alireza Alavi, Mark A. McKinlay, Srinivas K. Chunduru, John Silke, David Vaux, James Vince
-
Publication number: 20110003877Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.Type: ApplicationFiled: June 20, 2010Publication date: January 6, 2011Applicant: TETRALOGIC PHARMACEUTICALS CORPORATIONInventors: Stephen M. Condon, Yijun Deng, Matthew G. LaPorte, Susan R. Rippin
-
Publication number: 20100256046Abstract: Inhibitors of cIAP-1 and methods and compositions for treating proliferative disorders.Type: ApplicationFiled: April 3, 2009Publication date: October 7, 2010Applicant: TETRALOGIC PHARMACEUTICALS CORPORATIONInventors: Stacy SPRINGS, Mark McKINLAY, Sri CHUNDURU, Chris BENETATOS
-
Publication number: 20100143499Abstract: Compounds, compositions, and methods of using such compounds to modulate apoptosis including IAP antagonists are provided herein. Compositions including mimetics of the invention and, optionally, secondary agents, may be used to treat proliferative disorders such as, cancer and autoimmune diseases.Type: ApplicationFiled: July 24, 2007Publication date: June 10, 2010Applicant: TETRALOGIC PHARMACEUTICALS CORPORATIONInventor: Stephen M. Condon
-
Publication number: 20100144650Abstract: Compounds, compositions, and methods of using such compounds to modulate apoptosis including IAP antagonists are provided herein. Compositions including mimetics of the invention and, optionally, secondary agents, may be used to treat proliferative disorders such as, cancer and autoimmune diseases.Type: ApplicationFiled: July 24, 2007Publication date: June 10, 2010Applicant: TETRALOGIC PHARMACEUTICALS CORPORATIONInventor: Stephen M. Condon
-
Publication number: 20100113326Abstract: Compounds made up of a homodimer or heterodimer having monomeric units of formula (I): wherein: each A is, independently, NR1R2, or N+R1R2R3; each B is, independently, optionally substituted alkyl, alkenyl, or alkynyl, wherein one or more hydrogens are optionally replaced by fluorine; each U is, independently, CONH, C(O)O, C(S)O, C(S)NH, C(NH)NH, (CH2)1-5, or the inverse, thereof, wherein one or more carbons are optionally replaced by a heteroatom selected from O, S, and N; each V and W is, independently, (CH2)1-5, wherein one or more carbons are optionally replaced by C?O, C?S, or a heteroatom selected from O, S, and N, and one or more hydrogens are optionally replaced by a branched or unbranched alkyl or cycloalkyl, an optionally substituted aryl, arylalkyl, heteroaryl, heteroarylalkyl, OR4, SR4, or NR4R5; each X is, independently, optionally substituted alkyl, alkenyl, alkynyl, aryl, or heteroaryl, wherein one or more carbons are optionally replaced by C?O, C?S, or a heteroatom selected from O, S, and N, aType: ApplicationFiled: July 24, 2007Publication date: May 6, 2010Applicant: TETRALOGIC PHARMACEUTICALS CORPORATIONInventor: Stephen M. Condon
-
Publication number: 20100075911Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes.Type: ApplicationFiled: March 13, 2009Publication date: March 25, 2010Applicant: TETRALOGIC PHARMACEUTICALS CORPORATIONInventors: Stephen M. CONDON, Matthew G. LaPORTE, Yijun DENG, Susan R. RIPPIN
-
Publication number: 20100056495Abstract: Compounds, compositions, and methods of using such compounds to modulate apoptosis including IAP antagonists are provided herein. Compositions including mimetics of the invention and, optionally, secondary agents, may be used to treat proliferative disorders such as, cancer and autoimmune diseases.Type: ApplicationFiled: July 24, 2007Publication date: March 4, 2010Applicant: TETRALOGIC PHARMACEUTICALS CORPORATIONInventor: Stephen M. Condon
-
Patent number: 7517906Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes.Type: GrantFiled: February 27, 2006Date of Patent: April 14, 2009Assignee: TetraLogic Pharmaceuticals CorporationInventors: Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippin
-
Publication number: 20090048183Abstract: IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less that 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposes are also disclosed.Type: ApplicationFiled: October 9, 2008Publication date: February 19, 2009Applicant: TETRALOGIC PHARMACEUTICALS CORPORATIONInventors: Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippin
-
Patent number: 7456209Abstract: IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less that 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposes are also disclosed.Type: GrantFiled: July 15, 2005Date of Patent: November 25, 2008Assignee: Tetralogic Pharmaceuticals CorporationInventors: Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippin